Acceptability of bone antiresorptive therapy among HIV-infected adults at different stages of antiretroviral therapy

References

• BrownTTQaqishRBAntiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic reviewAIDS200620172165217417086056
   PubMed Web of Science ®Google Scholar
• TriantVABrownTTLeeHGrinspoonSKFracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare systemJ Clin Endocrinol Metab20089393499350418593764
   PubMed Web of Science ®Google Scholar
• BedimoRMaaloufNMZhangSDrechslerHTebasPOsteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agentsAIDS201226782583122301411
   PubMed Web of Science ®Google Scholar
• YoungBDaoCNBuchaczKBakerRBrooksJTHIV Outpatient Study (HOPS) InvestigatorsIncreased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000–2006Clin Infect Dis20115281061106821398272
   PubMed Web of Science ®Google Scholar
• AmorosaVTebasPBone disease and HIV infectionClin Infect Dis2006421081416323100
   PubMed Web of Science ®Google Scholar
• ThomasJDohertySMHIV infection – a risk factor for osteoporosisJ Acquir Immune Defic Syndr2003332819112843738
   PubMed Web of Science ®Google Scholar
• McComseyGAKitchDDaarESBone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202J Infect Dis2011203121791180121606537
   PubMed Web of Science ®Google Scholar
• StellbrinkHJOrkinCArribasJRASSERT Study GroupComparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT studyClin Infect Dis201051896397220828304
   PubMed Web of Science ®Google Scholar
• PapaioannouAMorinSCheungAMScientific Advisory Council of Osteoporosis Canada2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summaryCMAJ2010182171864187320940232
   PubMed Web of Science ®Google Scholar
• McComseyGATebasPShaneEBone disease in HIV infection: a practical review and recommendations for HIV care providersClin Infect Dis201051893794620839968
   PubMed Web of Science ®Google Scholar
• AbergJAGallantJEGhanemKGEmmanuelPZingmanBSHorbergMAPrimary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of AmericaClin Infect Dis201458111024343580
   PubMed Web of Science ®Google Scholar
• SimonJALewieckiEMSmithMEPetruschkeRAWangLPalmisanoJJPatient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover studyClin Ther200224111871188612501880
   PubMed Web of Science ®Google Scholar
• DouglasFPetrieKJCundyTHorneAGambleGGreyADiffering perceptions of intervention thresholds for fracture risk: a survey of patients and doctorsOsteoporos Int20122382135214022065304
   PubMed Web of Science ®Google Scholar
• AilingerRLHarperDCLasusHABone up on osteoporosis. Development of the Facts on Osteoporosis QuizOrthop Nurs199817566739832888
   PubMedGoogle Scholar
• FRAX WHO Fracture Risk Assessment Tool [Internet]University of Sheffield: World Health Organization Collaborating Center for Metabolic Bone Diseasec2011 Available at: http://www.shef.ac.uk/FRAX/tool.aspx?country=19Accessed August 11, 2014
   Google Scholar
• McClungMRWasnichRDHoskingDJEarly Postmenopausal Intervention Cohort StudyPrevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort StudyJ Clin Endocrinol Metab200489104879488515472179
   PubMed Web of Science ®Google Scholar
• RavnPBidstrupMWasnichRDAlendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trialAnn Intern Med19991311293594210610644
   PubMed Web of Science ®Google Scholar
• StochSASaagKGGreenwaldMOnce-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trialJ Rheumatol20093681705171419487264
   PubMed Web of Science ®Google Scholar
• AdachiJDSaagKGDelmasPDTwo-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trialArthritis Rheum200144120221111212161
   PubMed Web of Science ®Google Scholar
• GreenspanSLNelsonJBTrumpDLResnickNMEffect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trialAnn Intern Med2007146641642417371886
   PubMed Web of Science ®Google Scholar
• KlotzLHMcNeillIYKebabdjianMZhangLChinJLCanadian Urology Research ConsortiumA phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) studyEur Urol201363592793523040208
   PubMed Web of Science ®Google Scholar
• McComseyGAKendallMATebasPAlendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIVAIDS200721182473248218025884
   PubMed Web of Science ®Google Scholar
• MondyKPowderlyWGClaxtonSAAlendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infectionJ Acquir Immune Defic Syndr200538442643115764959
   PubMed Web of Science ®Google Scholar
• GuaraldiGOrlandoGMadedduGAlendronate reduces bone resorption in HIV-associated osteopenia/osteoporosisHIV Clin Trials20045526927715562367
   PubMed Web of Science ®Google Scholar